Narayana Hrudayalaya — the Henry Ford of heart surgery
Narayana Hrudayalaya Ltd
Snapshot
Narayana Hrudayalaya runs hospitals — 42 of them, ~5,554 beds, mostly in India plus the Cayman Islands and now the UK. Its whole reason for being is to do serious surgery cheaply: a heart operation for around ₹1.7 lakh that costs ten to fifty times more in America, with results as good or better. Market cap ₹38,393 cr, share price ₹1,879 (down from a ₹2,372 high), P/E 45, price-to-book 8.5×, return on equity 21%. As of 2026-06-20, from the screener snapshot.
What kind of business it is: a genuinely high-quality “Good” boat — healthy returns, but it has just started needing a lot more capital to grow.
The bottom line
| Lens | Result |
|---|---|
| QGLP score (Motilal Oswal) | 18 / 25 — Quality 9/12 · Growth 4.5/6 · Longevity 4.5/5 · Price 0/2 |
| Buffett rubric | 6 / 10 |
| Business bucket | Good — high quality, but capital intensity is rising |
| Wealth-creator type | Enduring franchise; profit was historically Volatile (covid + early losses), now steadier |
| Economic Profit | +₹404 cr (RoE 21% − cost of capital 12%, on ₹4,537 cr of owners’ money) — creating value, but the gap is shrinking |
| Margin-of-safety price band | ₹880–₹1,180 on strict value terms · CMP ₹1,879 is a full price — yet the cheapest of the listed hospitals |
A wonderful-ish business run by unusually good people, at a full price — and, oddly, the cheapest house on an expensive street.
In plain English
Imagine the best-run, lowest-priced heart hospital you’ve ever heard of, started by a surgeon who used to be Mother Teresa’s doctor and who decided that the poor shouldn’t die for lack of an operation. That’s Narayana. It does open-heart surgery on a kind of assembly line — high volume, every step engineered for cost — and gets death rates better than the American average at a tenth of the price. The Wall Street Journal called the founder “the Henry Ford of heart surgery.” It is not marketing; it’s how the place actually works.
For most of the last decade this was close to a great business hiding inside a usually-mediocre industry. Hospitals normally eat money — beds, scanners, buildings. Narayana grew its revenue for years without adding a single bed, just by running the ones it had harder and smarter. It collects from patients in about a month but pays its suppliers only after eight months, so it effectively runs on other people’s money. Nearly every rupee of profit turns into real cash. And in ten years on the market it has never once sold new shares to raise money. Those are the fingerprints of a special business.
Here’s the turn, and it’s the whole story. That “grow without spending” magic has run its course — profit has been roughly flat for three years (₹790 → ₹791 → ₹806 cr). So management has changed gears. In late 2025 they borrowed about ₹1,600 crore and bought a hospital chain in Britain — a mature, low-margin, heavily-regulated market a long way from their cost-engineering home turf. They’re also building expensive new hospitals in big cities and burning cash on a clinics-and-insurance experiment. Debt has roughly doubled and the return they earn on each rupee of capital has fallen from 32% to 15% in three years. The lean cash machine is becoming a capital-hungry grower.
That could be brilliant or it could be a mistake. The reason to give them the benefit of the doubt is that they have done exactly this before, and it worked: they built a hospital in the Cayman Islands the same patient, contrarian way and it now earns 40%+ margins. The reason to stay alert is that buying growth with debt in a foreign market is the one move where good operators most often trip.
And the price already assumes the good ending. At 45× earnings and 8.5× book there’s no safety cushion if returns keep slipping. The twist: every other listed Indian hospital — Apollo, Max, Fortis — is more expensive (62–72× earnings), and Narayana earns the highest return on equity of the lot. So it’s a full price in absolute terms and a bargain relative to its neighbours. Which of those two facts matters more depends on whether you’re a patient value investor or someone who has already decided to own a hospital.
Sitting down with the management
If Buffett and Raamdeo Agrawal spent an afternoon with these people, I think they’d leave impressed — and they’d write one item on a sticky note for the fridge.
Start with the founder, because the company is his character made concrete. Dr. Devi Shetty trained as a heart surgeon in England, came home, and was Mother Teresa’s cardiologist before he built Narayana in 2001. The line on his office wall is “Hands which help are better than the lips that pray.” His insight was almost embarrassingly simple and almost nobody else acted on it: if you do a great many operations and engineer the cost out of every step, you can make heart surgery cheap and safe at the same time, because volume itself buys both skill and scale. He proved it — and along the way co-designed a ₹5-a-month farmers’ insurance scheme and insisted it pay for itself rather than lean on the government forever. He became a billionaire as a by-product of running a low-margin mission, which is exactly the order Buffett likes those two things in. This is a builder, not an asset-gatherer.
Read his chairman’s letter and you stop worrying about whether he’s in it for the money. The FY25 letter barely mentions money. It’s about how their own AI software now writes a discharge summary in minutes instead of five hours, how sensors on a ward can flag a heart attack before it happens, and — my favourite — how he gives the hospital software away free to charitable hospitals in Kenya and Tamil Nadu. When one asked him why, he said: “by giving our EMR free of cost, I have not become poorer — and if I didn’t give it to them, that would not make us richer. This is the beauty of converting atoms into bytes.” (Agrawal, who literally wrote a Wealth Creation Study called “Atoms to Bits,” would have grinned.) A man who runs the Bangalore ICU at night through a doctor sitting in London is not managing a quarterly narrative.
Now the part that matters most to both masters: how they spend the owners’ money. Here the record is genuinely good, and one decision is a small classic. When they wanted to build the Cayman Islands hospital — a risky greenfield abroad — they did it as a junior partner, owning under 30% and letting a bigger partner fund the gamble. When it was de-risked and working, they bought the partner’s 71% stake for about $32 million. They let someone else pay to find out if it would work, then bought control cheaply once it did. That is textbook capital allocation — the rare rationality Buffett prizes. Ten years, zero share dilution, modest dividends, profit reinvested at high returns: the “one-dollar test” (does each retained rupee create at least a rupee of value?) passes comfortably on the historical record.
They also talk straight, which is rarer than it should be. Viren Shetty — the founder’s son, Stanford MBA, but a man who came up through the hospital engineering department, not a corner office — publicly admitted the insurance push flopped (≈75,000 policies against much bigger hopes), and said things no normal promoter says, like the plan is to “never dispute claims — we just pass the bill,” and that they’d happily “become worse as an insurer to be better as a healthcare company.” Admitting a miss by name, in plain words, is the single most reliable sign that a management isn’t fooling you — or itself.
Governance is clean. I went looking for the usual problems and didn’t find them: no promoter share pledging, no auditor qualifications, no related-party games (the procurement and other related entities are 100%-owned subsidiaries of the listed company, confirmed on the call), promoter family holding a stable ~63%. Profit is backed by cash year after year, and the balance sheet isn’t quietly bloating with the kind of “trash” that hides manipulation.
The sticky note for the fridge has three lines. One, Dr. Shetty is both Chairman and an executive — a proxy advisor has flagged the concentration of power, and at 72 he is the gravitational centre of the place (the two well-credentialled sons mitigate this, but don’t erase it). Two, his pay looks high in absolute terms (~₹14–15 cr — worth re-checking against profit each year; it’s a number to size, not yet a problem). Three, and most important, the leveraged UK acquisition is the first time they’ve bet real borrowed money in a market where their cost-engineering edge doesn’t obviously travel. None of these is a red flag. All three are the things you’d watch.
Would Buffett and Agrawal shake hands on this management? Yes — this is high on mission, candor, culture and a proven capital-allocation instinct, the kind of people you’re happy to leave alone for a decade. What would change their mind: if the UK deal turns into the kind of foreign empire-building that ends up “kissing toads,” or if the falling return on capital keeps falling without the growth to show for it.
QGLP scorecard (the Motilal Oswal lens) — the receipts
RoE = profit per ₹100 of owners’ money. RoCE = profit per ₹100 of all capital. OPM = operating margin. Negative working capital = suppliers fund the business.
| # | Question | Score | Evidence |
|---|---|---|---|
| Quality of Business | 4.0/6 | ||
| 1 | Large opportunity? | 1 | India is badly short of hospital beds; + UK/Cayman optionality. Decade-plus runway. |
| 2 | Industry structured well? | 0.5 | Inelastic demand, organised gaining share — but capital-heavy, competitive, price-cap risk. India margins rising 21→25%. |
| 3 | Defensible moat? | 0.5 | Cost-leadership + brand + negative working capital. But the high-return proof is only ~4–5 years old, and RoCE is falling (32%→15%). |
| 4 | Return ratios >15%? | 0.5 | RoE 21%, RoCE 15% now — but RoCE was 7–14% before FY22 and is sliding; not a 10-year record. |
| 5 | Asset-light? | 0.5 | Historically yes (“no new beds,” cash conversion ~110%). Now reversing — FY26 fixed assets nearly doubled. |
| 6 | Favourable Terms of Trade? | 1 | Cash-conversion cycle −181 days; pays suppliers in 248 days, collects in 30. A real cash engine. |
| Quality of Management | 5.0/6 | ||
| 7 | Integrity? | 0.5 | Founder-led, 63% promoter, no pledge, profit cash-backed. Minor: screener flags possible interest-cost capitalisation. |
| 8 | Execution? | 1 | Delivered India margin 21→25%, scaled Cayman to 40%+ margins, proven turnaround playbook. |
| 9 | Growth mindset? | 1 | UK entry, integrated care + insurance, AI/digital, new hospitals. |
| 10 | Capital allocation? | 0.5 | Superb record (zero dilution in a decade, the Cayman buyout) — but the debt-funded UK bet is unproven. |
| 11 | Succession? | 1 | Founder + two ops-grounded sons (Stanford/MIT) + pro CXOs. |
| 12 | Minority interests? | 1 | No dilution, related parties are 100% subsidiaries, transparent. |
| Growth | 4.5/6 | ||
| 13 | Structural tailwind? | 1 | Healthcare growing well above GDP (under-penetration, insurance, ageing). |
| 14 | Volume-led? | 0.5 | Recent India growth is realisation/mix-led — efficiency has a ceiling; now adding capacity. |
| 15 | Operating leverage? | 1 | India margin 21→25% on higher realisations. |
| 16 | Manageable leverage? | 0.5 | Debt/equity jumped to ~1.3× (from 0.67×) on the £150m UK loan; interest cost ₹163→₹244 cr. |
| 17 | Market-share gains? | 1 | Organised share gains + footprint/international expansion. |
| 18 | Earnings growth >15%? | 0.5 | Profit has been flat 3 years (₹790→₹806 cr). The optical 5-yr CAGR flatters off the covid base. |
| Longevity | 4.5/5 | ||
| 19 | Relevant 10–15 yrs? | 1 | Physical hospital care is durable and hard to disrupt. |
| 20 | Extend the moat (CAP)? | 0.5 | Cost model + brand support it, but the return spread is compressing as it reinvests. |
| 21 | Long growth runway (GAP)? | 1 | Big market, low penetration, international optionality. |
| 22 | Diversification headroom? | 1 | Geography (UK/Cayman/tier-2) + adjacencies (insurance, clinics, software). |
| 23 | Adaptive culture? | 1 | Proven transformation, real innovation, survived covid. |
| Price | 0/2 | ||
| 24 | Valuation reasonable? | 0 | P/E 45, P/B 8.5×. PEG well above 2 on any realistic growth. |
| 25 | Margin of safety? | 0 | 5-yr payback ≈ 6× (below). No cushion at this price. |
| Total | 18.0/25 |
The shape is clean: quality and longevity are strong (18 of the 23 non-price points); the whole shortfall is Price — plus a real, live erosion in returns as the company shifts from efficiency to capital-led growth.
The Buffett rubric — the receipts
| # | Test | Result | Why |
|---|---|---|---|
| 1 | Good boat? | PARTIAL | Healthcare is durable, but hospitals are capital-heavy. NH ran it Great-style; now drifting to “Good.” |
| 2 | Moat + pricing power | PARTIAL | Real cost + brand moat — but the edge is being cheapest, not raising prices. High returns only ~5 years old. |
| 3 | See’s test (returns on little capital) | PARTIAL | Was a clear pass (no new beds, cash-rich) — now reversing into debt-funded capex. |
| 4 | One-dollar test (capital allocation) | PASS | Zero dilution in a decade; the Cayman buyout; value created per rupee retained. |
| 5 | Owner-oriented, candid mgmt | PASS | Founder, 63% stake, gives software away, admits misses in plain words. |
| 6 | Integrity / cash-backed profit | PASS | Cash ≈ or > profit every year; debtor days falling. Minor capitalisation watch. |
| 7 | Circle of competence / predictability | PARTIAL | India core is simple; the UK + insurance pivot adds complexity. |
| 8 | Mr. Market — gift or trap now? | FAIL | 45× earnings, 8.5× book even after a 21% fall. Not a fearful price. |
| 9 | Patience / compounding runway | PASS | Long runway in under-served Indian healthcare + abroad. |
| 10 | The honest red flag | (see Conviction) | — |
The See’s Candy test, in one breath. For years Narayana was a See’s-style machine: it grew without adding beds, ran on its suppliers’ money, and turned almost all its profit into cash. FY26 partly broke the spell — fixed assets nearly doubled and borrowings jumped from ₹2,428 cr to ₹5,857 cr to buy the UK business, and the return on capital fell to 15%. It is now feeding capital to grow. A “Good” company, no longer a pure “Great” one.
The one-dollar test, in one breath. Equity capital has sat flat at ₹204 cr for ten years — they have never diluted you — and the market value created on retained profit has been enormous. Pass. The only unanswered rupee is the one borrowed for Britain.
The framework metrics
- Economic Profit = ₹4,537 cr of owners’ money × (RoE 21% − cost of capital 12%) = +₹404 cr. Real value created — but the spread (9%) is narrowing, and some of that 21% is now borrowed.
- Terms of Trade = strongly favourable. Collects in ~30 days, pays in ~248; works negative through the whole history.
- 5-year payback ≈ 6× (market cap ÷ a generous 15%-growth projection of five years’ profit). The multibagger signal is <1×; this is nowhere near.
- PEG = 45 ÷ growth → above 2.5 even on a hopeful mid-teens forward, absurd on the ~1% recent reality.
- RoE − cost of capital spread = +9%; RoE above 15% in only about 5 of the last 10 years — the “emergence” of uncommon profit, not yet a proven decade of it.
- Consistent vs Volatile = fails the strict test — profit fell hard in FY18 and went negative in FY21 (covid). Historically a Volatile; the last four years far steadier.
Peer comparison (listed premium hospitals)
Screener snapshots, 2026-06-20. Margins are blended group OPM — NH’s is dragged by the new low-margin UK book; India-only is ~25%.
| Metric | NH | Apollo | Max | Fortis |
|---|---|---|---|---|
| Market cap | ₹38,393 cr | ₹1,22,066 cr | ₹1,06,546 cr | ₹72,699 cr |
| P/E | 45.1 | 62.4 | 71.8 | 68.7 |
| P/B | 8.5× | 12.9× | 10.0× | 7.4× |
| RoE | 20.9% | 22.1% | 14.8% | 11.3% |
| RoCE | 15.4% | 17.9% | 14.7% | 13.5% |
| OPM (blended) | 20% | 15% | 27% | 23% |
| Latest sales | ₹7,896 cr | ₹25,228 cr | ₹8,373 cr | ₹9,128 cr |
Two facts, and both help NH on price. First, it is the cheapest of the four on earnings (45× vs 62–72×) while earning the highest return on equity. So “a full price” is true against an absolute yardstick but false against its own neighbours. Second, the whole street trades at 45–72× — the market permanently pays up for healthcare durability, so a strict “cheap” entry essentially never appears here. Apollo is the scale + pharmacy/diagnostics ecosystem; Max is the margin star on premium metros; Fortis is the lower-return turnaround. Narayana’s distinctive edge is the low-cost, no-dilution, cash-generative model plus international optionality none of the others has at this scale.
What’s on the horizon (live-issues tracker)
Latest print: Q4 FY26 (quarter ended Mar 2026), reported 26 May 2026 — group sales ₹2,594 cr, margin ~20%, profit ₹224 cr. Five things will decide the next three years. Here’s each, and how it’s tracking.
1. The UK bet, up close — Practice Plus Group 🟡 too early, well-structured
This is the big one — the move that doubled the debt and reshaped the company, so it’s worth understanding properly.
What they bought. On 6 November 2025 NH bought Practice Plus Group’s hospitals division — the 5th-largest private hospital network in Britain — from private-equity owner Bridgepoint. It’s 7 hospitals plus a handful of surgical and diagnostic centres, ~330 beds, ~80,000 surgeries a year, ~2,500 staff. It does high-volume routine surgery — hip and knee replacements, cataracts, general surgery. They bought only the hospitals; they deliberately left behind PPG’s NHS-111 call-centres and its prison-healthcare arm. (LaingBuisson, PL Capital note, both Oct–Nov 2025.)
What they paid, and how. £183m enterprise value (~₹2,000 cr), about 9× clean operating profit — though counting the loss-making new Birmingham hospital the effective price is nearer 13×. Funded with £150m of debt + ~£40m equity, and here’s the elegant bit: the equity came out of Cayman’s spare cash, not India, and the debt sits in the UK and is repaid in pounds by the UK business itself (cost ~6%, a 2+5-year schedule). So India’s owners didn’t fund the equity and don’t carry the loan’s currency risk. The business came debt-free. That is a carefully de-risked financing — the kind Buffett would nod at.
Why it’s interesting and not just a punt. Unlike most acquisitions, the revenue is unusually safe: ~93% is long-term contracted NHS work — “evergreen” contracts, inflation-linked, paid within about 15 days, almost no working capital. So this isn’t a bet on demand showing up. It’s a bet on one thing only: margins. Today PPG earns ~8–10% operating margin against NH India’s ~25%. Two levers to lift it: (a) NH’s software and process-engineering — Viren noted PPG runs “several systems, none of which talk to each other,” with people retyping data between them, exactly what their Athma platform kills; and (b) shifting the patient mix toward private-pay, who pay 20–35% more than the NHS. PPG is at just 7–8% private; rivals run 30–75%. And the hospitals are only 50–55% full, so there’s room to grow into. Management’s stated aim: lift the UK to “high-teens” margins and group return-on-capital back to 20–22% by FY29/30.
How it’s going so far — genuinely too early, by management’s own honesty. First two quarters in, the UK is margin-dilutive and running a small net loss (~£1.9m / ₹34 cr in Q4), with transition costs and an unfinished IT separation from the seller muddying the numbers. EBITDA margin has nudged 8% → ~10%, but the CFO says wait a few clean quarters before believing it. They themselves warn the UK will never reach Cayman margins. Timeline to real results: “2–3 years or more, no guidance.”
The one risk they can’t control — and a fresh warning light. That safe 93% NHS revenue is only as safe as the government’s willingness to outsource. Policy currently helps (the Labour Elective Reform Plan leans on private hospitals to clear a 6-million-patient backlog). But in the same window, Spire — the UK’s largest private hospital chain — issued a profit warning that the NHS is reining in independent-sector spending, guiding NHS volumes ~25% lower in early 2026. That is the canary for PPG. If the NHS tightens the tap, the floor under this deal moves.
The two-sided read. Bull: a cheaply-bought (9×), debt-free, cash-generative, NHS-backed platform at half-occupancy, with a clear private-pay margin lever and a management that’s pulled off exactly this in Cayman — a broker (PL Capital) already rates it Buy at ₹2,000. Bear: a 93%-NHS-dependent, ~10%-margin business bought with leverage into a market where the leader just warned on volumes, betting that an Indian cost edge and an unproven private-pay pivot can roughly double profit in a market nothing like India.
2. India hospitals — the crown jewel 🟢 on track
The home business keeps quietly getting better: margin 21.5% → 25.1% year-on-year, driven by high-end work (robotic cardiac surgery, transplants) and better realisations — still without adding beds. This is the engine that funds everything else and it’s firing. Watch whether the margin holds as new-city hospitals (higher cost) come on.
3. India capex ramp 🟡 deliberate, watch returns
Management has guided ~₹3,000 cr over three years into new and brownfield hospitals — a real break from the old “no new beds” model, partly because construction costs are 60% higher than five years ago. This is the main reason return-on-capital has fallen. Necessary for growth, but it’s the spend to watch: new hospitals lose money for a couple of years before they fill.
4. India clinics + insurance (“One Health”) 🟡 honest about the miss
The integrated-care experiment is still burning cash, and management has openly admitted take-up disappointed (~75,000 policies vs hopes). Each clinic needs ~18 months to break even. They’re folding it into the core to share overheads and slowing the rollout. Strategically a feeder for the hospitals; financially a drag for now. Their candor here is a plus; the losses are a minus.
5. AI / software — the free option 🟢 emerging
Their own Athma/Medha platforms cut a discharge summary from five hours to minutes and were cited by the NHS England 10-year-plan white paper. They’re starting to license the software to other hospitals (and gave it free to charity hospitals). Capital-light, early, unquantified — but a genuine optional extra leg.
The watch-list (check these next quarter)
- UK margin — does it move convincingly past ~10% toward the mid-teens once transition costs and IT separation clear (2–3 clean quarters)?
- NHS outsourcing policy — does the Spire-style “NHS reining in spend” warning spread to PPG’s contracted volumes? This is the deal’s real risk.
- Return on capital — does the group RoCE stop falling (it’s gone 32% → 15% in three years) and start the climb back toward management’s 20–22% FY29/30 target?
- Group profit — does it finally break out of its three-year plateau (₹790 → ₹806 cr)?
- Debt + interest — net debt/equity (0.53 at Dec-2025) and the interest-capitalisation note in the FY26 annual report.
- India hospital margin — does ~25% hold as higher-cost new-city hospitals open?
Where the two lenses agree — and disagree
They agree on the core: a durable, well-run, brand-and-cost-moated franchise with excellent historic capital discipline and a long runway — and they agree the price gives no margin of safety (Price 0/2; Mr. Market test FAIL). 18/25 and 6/10 line up: strong quality, gated by valuation.
The interesting disagreement is about the business trajectory. The Motilal Oswal checklist still banks the historic quality (negative working capital, no dilution, high RoE). But the Buffett See’s test catches what a checklist softens: the FY26 doubling of assets and debt means the asset-light “Great” machine is actively becoming a capital-fed “Good” one, and the return on capital falling 32%→15% is the early evidence. Trust the Buffett flag here — the quality is real but peaking on the very measure Buffett cared about most, just as the price demands perfection.
The price
Not a recommendation — just the arithmetic. At ₹1,879 you’re paying about 45× this year’s earnings. A strict value entry (where each rupee of price is backed by enough growth) would want ~15–18× (≈ ₹600–700) — but no premium Indian hospital ever trades there, so that bar is academic. A “fair, not heavily front-paid” entry for a mid-teens grower of this quality is ~22–30×: ₹880 to ₹1,180. CMP sits 50–110% above that.
The honest caveat: against its own peers, NH at 45× is the least expensive name in a 45–72× sector, and it earns the best returns. So the patient value investor (who can wait years for a fearful price) and the sector allocator (who has decided to own a hospital and wants the best one cheapest) get genuinely different answers. Both are true; pick your frame.
Conviction texture
The bull case, at full strength: India’s best-run, lowest-cost hospital operator — founder-led, perfectly aligned, never dilutes you — riding a multi-decade shortage of hospital beds, now exporting a proven integrated-care model from Cayman to Britain. If the UK turns out like Cayman, today’s “expensive” multiple will look cheap in five years, and the AI/software arm is a free option on top.
The bear case, at full strength (the honest red flag): Narayana is spending up — debt, a low-margin UK business, cash-burning clinics — precisely because its famous “grow without spending” model has run dry: profit has been flat for three years. The numbers back the worry — return on capital has fallen from 32% to 15% and debt has doubled. If Britain disappoints — and the UK market leader Spire has just warned the NHS is cutting independent-sector volumes — or India price-caps bite, or insurance losses linger, you own a now-capital-heavy hospital chain at 45× earnings and 8.5× book with no cushion. Even reported profit deserves a second look while they’re capitalising costs during heavy building.
What the numbers actually support: a genuinely high-quality, enduring franchise, run by people you’d trust, that is mid-transition — returns compressing, and a price that already pays for the happy ending.
What to watch: (1) UK margins over the next 2–3 quarters — do they climb toward double digits and stay; (2) return on capital — does it steady or keep sliding; (3) profit growth breaking out of its three-year plateau; (4) debt and the interest-capitalisation note in the FY26 annual report; (5) the clinics/insurance losses narrowing.
Sources
- Screener.in: https://www.screener.in/company/NH/consolidated/ (snapshot fetched 2026-06-20); FY24 & FY25 annual reports (chairman’s & CEO letters, governance/RPT sections).
- Earnings concalls: Aug 2025 (Q1), Nov 2025 (Q2 — deal-closing call), Feb 2026 (Q3 — first UK consolidation), May 2026 (Q4). UK deal mechanics, margins and management’s value-creation thesis quoted from these.
- Management/promoter research: HBS case Narayana Hrudayalaya: Cardiac Care for the Poor; NPR/WSJ “Henry Ford of heart surgery” profiles; The Ken & NDTV Profit interviews with Viren Shetty; SES proxy report (2022, Chairman-executive flag); company disclosures. Promoter remuneration figure from aggregator sources — verify in the FY25 annual report.
- UK (Practice Plus Group) deal research: NH acquisition call transcript (3 Nov 2025); PL Capital broker note (4 Nov 2025, Buy TP ₹2,000); LaingBuisson (31 Oct 2025); Business Standard (31 Oct 2025); Moneycontrol/HBI interviews with Viren Shetty; Spire Healthcare H1-2025 results + profit warning; UK Health Foundation on the Elective Reform Plan. PPG ≈93% NHS revenue, ~£183m / ~9× clean EBITDA, 50–55% occupancy, hospitals-only (excl. NHS-111 & Health in Justice).
- Assumptions: cost of equity 12% (mid of the studies’ 10–15%); 5-yr payback uses a generous 15% profit growth (vs the recent ~1%).
- No buy/sell/hold — quality verdict, management read, and price band only.